Clinical Evidence for JAK Inhibition in Alopecia Areata: A Comprehensive Review

    January 2026
    S. Manoj Gowda, Saransh Verma, Savi Gadegone … Somesh Gupta
    Studysummary JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jhrrm.org →
    Discuss this study in the Community →

    Research cited in this study 22

    1. Switching JAK Inhibitors: Evaluating Baricitinib’s Effectiveness in Alopecia Areata After Tofacitinib Failure Archives of Dermatological Research · 2025
    2. Relapse Of Alopecia Areata Responders After Tofacitinib Withdrawal: A Retrospective Study Of 59 Patients Journal of Cutaneous Medicine and Surgery · 2025
    3. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    4. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System Military medicine · 2024
    5. Effectiveness of Tofacitinib in Pre-Adolescent Alopecia Areata: A Retrospective Case Series and Literature Review Acta dermato-venereologica · 2023
    6. Janus Kinase Inhibitors for Alopecia Areata Journal of the American Academy of Dermatology · 2023
    7. Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review Indian journal of dermatology, venereology, and leprology · 2023
    8. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
    9. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    10. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    11. Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population Dermatologic Therapy · 2022
    12. Recovery of Resistant Alopecia Areata Treated with Tofacitinib: An 8-Year-Old Child's Case Report International Journal of Trichology · 2022
    13. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    14. Treatment of Alopecia Areata in Pre-Adolescent Children with Oral Tofacitinib: A Retrospective Study Pediatric Dermatology · 2020
    15. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    16. Response to Tofacitinib Therapy of Eyebrows and Eyelashes in Alopecia Areata Journal of the American Academy of Dermatology · 2018
    17. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    18. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    19. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    20. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    21. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
    22. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010